Abatacept or infliximab for patients with rheumatoid arthritis and inadequate response to methotrexate: an Italian trial-based and real-life cost-consequence analysis

Benucci M, Stam WB, Gilloteau I, Sennfalt K, Leclerc A, Maetzel A, Lucioni C

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
23711100

Indexing Status
Subject indexing assigned by NLM

MeSH
Abatacept; Adult; Antibodies, Monoclonal /administration & dosage /adverse effects /economics; Antirheumatic Agents /administration & dosage /adverse effects /economics; Arthritis, Rheumatoid /drug therapy /economics; Double-Blind Method; Drug Costs; Drug Resistance; Drug Therapy, Combination; Female; Health Care Costs; Humans; Immunoconjugates /administration & dosage /adverse effects /economics; Infliximab; Italy; Male; Methotrexate /administration & dosage /adverse effects /economics; Middle Aged; Placebos; Remission Induction

AccessionNumber
22013044590

Date bibliographic record published
31/10/2013